CURRICULUM VITAE

26 September 2013

SEAN R. TUNIS M.D., M.Sc.

CURRENT APPOINTMENTS

Founder, President, and CEO, Center for Medical Technology Policy
Director, HTAi Board of Directors
Adjunct Assistant Professor in Medicine, Johns Hopkins University, School of Medicine
Adjunct Professor of Medicine, Tufts University, School of Medicine
Adjunct Faculty, Stanford University, Center for Health Policy
Adjunct Faculty, University of California San Francisco, School of Medicine

[redacted]

[redacted]

BUSINESS ADDRESS

401 E. Pratt Street, Suite 631, Baltimore, Maryland 21202
Office: 410-547-2687[redacted] • Fax: 410-547-5088
Email: sean.tunis@cmtpnet.org • Web: www.cmtpnet.org

EDUCATION & TRAINING

1989 – 1991	**Graduate courses** in epidemiology and biostatistics, Johns Hopkins University, School of Public Health and Hygiene
1987 – 1989	**Residency**, Department of Medicine, University of Maryland Hospital, Baltimore, MD
1986 – 1987	**Internship**, Departments of Medicine and Emergency Medicine, University of California at Los Angeles Hospital, Harbor-UCLA Medical Center, Los Angeles, CA
1983 – 1984	**M.Sc. Health Services Research**, Minor in Communication Theory Stanford University, Stanford, CA
1980 – 1986	**M.D. Degree**, Stanford University School of Medicine, Stanford, CA
1975 – 1980	**B.S. Degree** in Biology Specialization in Neurobiology, Joint degree in History of Science, Cornell University, Ithaca, NY

PROFESSIONAL EXPERIENCE

2005 – Present	**Founder**, **President, and CEO,** Center for Medical Technology Policy (CMTP)
2002 – 2005	**Director**, Office of Clinical Standards and Quality, Chief Medical Officer,

	Centers for Medicare and Medicaid Services (CMS)
1991 – 2005	**Attending Physician**, Emergency Department, Mercy Hospital, Baltimore, MD
2000 – 2002	**Director for Group Coverage**, Coverage and Analysis Group (CAG), Office of Clinical Standards and Quality, Centers for Medicare and Medicaid Services (CMS)
1997 – 2006	**Senior Research Scientist and Vice President**, The Lewin Group, San Francisco, CA
1992 – 1995	**Director**, Health Program, Congressional Office of Technology Assessment
1991 – 1992	**Congressional Science Fellow**, United States Senate, Committee on Labor and Human Resources Health Office
1989 – 1991	**Fellow**, Division of General Internal Medicine, Program for Medical Technology and Practice Assessment, Department of Medicine, Johns Hopkins School of Medicine

CERTIFICATIONS

License:	Maryland D37634 (active)
Certification:	National Board of Medical Examiners (1986)
	American Board of Internal Medicine (1990)

HONORS AND AWARDS

2012	1st Annual CER National Leadership Award, Institute for Clinical and Economic Review
2001	Government Special Contribution Award, Medical Device Manufacturers Association
2001	CMS Administrator's Achievement Award
2000	CMS Administrator's Achievement Award
1992	Selected as a Health Policy Fellow by the Milbank Memorial Fund and the Congressional Office of Technology Assessment
1991	Selected as a Congressional Fellow by the American Association for the Advancement of Science
1986	Stanford Alumni Association Award for Excellence in Medical Student Research
1980	B.S. Degree with Honors and Distinction
1975 – 1979	Thomas J. Watson Scholarship, National Merit Scholarship Program

TEACHING POSITIONS

1991 – 2003	**Clinical Instructor in Emergency Medicine**, Emergency Medicine Residency Program University of Maryland Medical School

1989 – 1991	**Senior Clinical Fellow**, Department of Medicine, The Johns Hopkins Hospital
1984	**Teaching Assistant**, Health Care and Public Policy, Department of Human Biology, Stanford University
1982 – 1983	**Teaching Assistant**, Psychopharmacology, Department of Human Biology, Stanford University
1981	**Teaching Assistant**, Introductory Biology, Department of Biological Sciences, Stanford University
1978 – 1979	**Teaching Assistant**, Biochemistry, Department of Biological Sciences, Cornell University

COMMITTEE MEMBERSHIPS

2012 - Present	**Task Force Member,** AACR, Health Policy Task Force
2012 - 2015	**Committee Member**, ISPOR Health Science Policy Council
2011 – Present	**Committee Member**, Cancer Steering Committee, The Biomarkers Consortium, National Institutes of Health
2011 – Present	**Working Group Member**, Evaluation of Genomic Applications in Practice and Prevention (EGAPP)
2009	**Committee Member:** Institute of Medicine, Priorities for Comparative Effectiveness Research
2008 – 2009	**Planning Committee Member**, Institute of Medicine, Summit on Integrative Medicine and the Health of the Public
2008 – 2009	**Planning Committee Member,** Institute of Medicine, Assessing and Improving the Value of Cancer Care
2007 – Present	**Editorial Board**, International Society of Technology Assessment in Health Care
2005 – 2008	**Editorial Board,** Health Affairs
2003 – Present	**National Advisory Board**, US Cochrane Collaboration
2003 – Present	**Editorial Board,** American Journal of Managed Care
2003 – 2005	**Steering Committee**, National Health Policy Forum
2001 – 2005	**CMS Representative:** Secretary's Advisory Committee on Genetics, Health and Society, Department of Health and Human Services
2000 – 2004	**VA Clinical Studies Review Panel**, Cooperative Clinical Trials Program

PROFESSIONAL SOCIETIES

Member	Health Technology Assessment International
Member	AcademyHealth

MANUSCRIPT AND ABSTRACT REVIEWS

1. Journal of the American Medical Association
2. Annals of Internal Medicine
3. Health Affairs
4. International Journal of Technology Assessment in Health Care
5. New England Journal of Medicine
6. Milbank Quarterly
7. American Journal of Managed Care

RESEARCH EXPERIENCE

1. **Investigator**, Diffusion patterns in adoption of percutaneous transluminal angioplasty: a network analysis. PMTPA and Carnegie Mellon Department of Statistics, 1990 to 1992
   We are applying quantitative techniques of network analysis to define hospital characteristics which are associated with differing rates of adoption of a new technology (PTA) in Maryland from 1979 to 1989.
2. **Co-principal Investigator,** Physicians' attitudes toward practice guidelines, PMTPA and American College of Physicians Funded by the ACP to conduct a national mailed survey of 2500 ACP members to document attitudes and knowledge regarding clinical practice guidelines.
3. **Principal Investigator**, New technology for treatment of peripheral vascular disease, Program for Medical Technology and Practice Assessment (PMTPA), 1989 to 1992
   Analyzed claims data from the Maryland Health Services Cost Review Commission to assess the diffusion of balloon angioplasty as a treatment for peripheral vascular disease, and variations in treatment patterns for PVD.
4. **Co-Investigator**, Cost and outcomes of coronary bypass surgery, Institute for Health Policy Studies and Blue Shield Education and Research Foundation, San Francisco, CA, 1985 to 1986
   Served as the study coordinator for an analysis of the relationship between volume of bypass surgery and mortality rate, as well as determination of episode-of-illness costs for bypass.
5. **Co-Investigator**, Exercise rehabilitation in myocardial infarct patients, Cardiac Rehabilitation Program, Division of Cardiology, Stanford Medical School, Stanford, CA, 1983 to 1985
   Developed and evaluated an audiovisual program for post-MI patients to educate and motivate them in their exercise rehabilitation program.

PUBLICATIONS

1. **Tunis SR**, Messner DA. Medicare policy on bariatric surgery: decision making in the face of uncertainty. J Amer Med Assoc. 2013: doi:10.1001/jama.2013.278849

2. Sonnad SS, Mullins CD, Whicher D, Goldsak J, Mohr PE, **Tunis SR**. Recommendations for the Design of Phase 3 Pharmaceutical Trials that are more Informative for Patients, Clinicians, and Payers. Contem Clin Trials. 2013:pii:S1157-7144(13):132-138.

3. Sonnad SS, Goldsack JC, Mohr PE, **Tunis SR**. Methodological recommendations for comparative research of the treatment of chronic wounds. J Wound Care. 2013;22(9):470-480. PMID: 24005781.

4. Faden RR, Kass, NE, Whicher DM, Stewart W, **Tunis SR**. Ethics and informed consent for comparative effectiveness research with prospective electronic clinical data. Med Care. 2013;51(8 Suppl 3):S53-7. doi: 10.1097/MLR.0b013e31829b1e4b. PMID: 23793051 [PubMed - in process]

5. Buttorff CA, **Tunis SR**, Weiner JP. Encouraging value-based insurance designs in state health insurance exchanges. Am J Manag Care. 2013;19(7):593-600. PMID: 23919422 [PubMed - in process]

6. Evaluation of Genomic Applications in Practice Prevention Working Group. Recommendations from the EGAPP Working Group: does genomic profiling to assess type 2 diabetes risk improve health outcomes? Genet Med. 2013:15(8):612-617. doi:10.1038/gim.2013.9

7. Calonge N, Fisher NL, Berg AO, et al. Recommendations from the EGAPP Working Group: can testing of tumor tissue for mutations in EGFR pathway downstream effector genes in patients with metastatic colorectal cancer improve health outcomes by guiding decisions regarding anti-EGFR therapy? Genet Med. 2013; doi: 10.1038/gim.2012.184. PMID: 23429431. **[Epub ahead of time.]**

8. Kass NE, Faden RR, Goodman SN, Pronovost P, **Tunis SR**, Beauchamp TL. The research-treatment distinction: A problematic approach for determining which activities should have ethical oversight. Hastings Center Report. 2013;43(s1):S4-S15. doi:10.1002/hast.133

9. Faden RR, Kass NE, Goodman SN, Pronovost P, **Tunis SR**, Beauchamp TL. An ethics framework for a learning health care system: A departure from traditional research ethics and clinical ethics. Hastings Center Report. 2013:43(s1):S16-S27. doi:10.1002/hast.134

10. Ramsey SD, Barlow WE, Gonzalez-Angulo AM, **Tunis SR**, Baker L, Crowley J, Deverka PA, Veenstra D, Hortobagyi GN. Integrating comparative effectiveness design elements and endpoints into a phase III, randomized clinical trials (SWOG S1007) evaluating oncotypeDX-guided management for women with breast cancer involving lymph nodes. Contemp Clin Trials. 2013;34(1):1-9. doi:10.1016/jcct.2012.09.003. PMID:23000081 {PubMed – in process) PMCID: PMC3525786

11. Veenstra DL, Piper M, **Tunis SR**, et al. Improving the efficiency and relevance of evidence-based recommendations in the era of whole-genome sequencing: an EGAPP methods update. Genet Med. 2013;15(1):14-24. doi: 10.1038/gim.2012.106. PMID: 22955111

12. **Tunis SR**. Improving comparative effectiveness research: New methodological standards focus on quality and relevance of research to patents. BMJ. 2012;345:e5160

13. Kass N, Faden R, **Tunis SR**. Addressing low-risk comparative effectiveness research in proposed changes to US federal regulations governing research. JAMA. 2012;307(15):1589-1590. doi:10.1001/jama.2012.491. PMID:22511685

14. Campbell B, Patrick H; REGISTER GROUP – **Tunis SR**. International collaboration in the use of registries for new devices and procedures. Br J Surg. 2012;99(6):744-745. doi:10.1002/bjs.8791. PMID: 22508386

15. Mullins CD, Montgomery R, Abernethy AP, Hussain A, Pearson SD, **Tunis SR**. Recommendations for clinical trials of off-label drugs used to treat advanced-stage cancer. J Clin Oncol. 2012;30(6):661-666. doi:10.1200/JCO.2011.35.5198. PMID: 22253467

16. Schwartz S, Lauer M, McNeil B, **Tunis SR**, Diamond Guy, Silber J, Herzig A, Lauer M, Temple B, Lee J, Rhodes K, Morton S, Rotelli M. Panel discussion 1. Clin Trials. 2012;9(1):13-21. doi:10.1177/1740774511433047. PMID: 22334464

17. Salimi T, Lehner JP, Epstein RS, **Tunis SR**. A framework for pharmaceutical value-based innovation. J Comp Effect Res. 2012; 1(1s):3-7. doi:10.2217/cer.11.2

18. Goddard KA, Knaus WA, Whitlock E, Lyman GH, Feigelson HS, Schully SD, Ramsey SD, **Tunis SR**, Freedman AN, Khoury MJ, Veenstra DL. Building the evidence base for decision making in cancer genomic medicine using comparative effectiveness research. Genet Med. 2012; 14(7):633-642. PMID:22516979

19. Bekelman JE, Deye JA, Vikram B, **Tunis SR**, et al. Redesigning radiotherapy quality assurance: Opportunities to develop an efficient, evidence-based system to support clinical trials. Report of the national cancer institute work group on radiotherapy quality assurance. Int J Radiat Oncol Biol Phys. 2012;83(3) 782-790. doi:10.1016/j.ijrobp.2011.12.080. PMID: 22425219 [PubMed - indexed for MEDLINE] PMCID: PMC3361528

20. Gliklich RE, Leavy MB, Velentgas P, Dreyer NA, **Tunis SR**, Mohr PE, Messner DA, Moloney RM, Karkare SU, DuBois RW, Graff JS. Incorporating stakeholder perspectives in developing a translation table framework for comparative effectiveness research. J Comp Eff Res. 2012; 1(3), 281-292. doi: 10.2217/cer.12.25

21. **Tunis SR**, Turkelson CM. Using health technology assessment to identify gaps in Evidence and inform study design for comparative effectiveness research. J Clin Oncol. 2012;30(34):4256-4261. doi:10.1200/JCO2012.42.6338.

22. Basch E, Abernethy AP, Mullins CD, Spencer MR, **Tunis SR**, et al. Recommendations for incorporating patient-reported outcomes into clinical comparative effectiveness research in Adult Oncology. J Clin Oncol. 2012;30(34); 4249-4255. doi:10.1200/JCO.2012.42.5967. PMID:23071244

23. **Tunis SR**, Messner DA, Mohr PE, Gliklich RE, and Dubois RW. A translation table for patient-centered comparative effectiveness research — Guidance to improve the value of research for clinical and health policy decision making. J Comp Eff Res. 2012;1(3), 259-262. ISSN 2042-6305. doi:10.2217/cer.12.22.

24. Witt CM, Aickin M, Baca T, Cherkin D, Haan MN, Hammerschlag R, Hao JJ, Kaplan GA, Lao L, McKay T, Pierce B, Riley D, Ritenbaugh C, Thorpe K, **Tunis SR**, Weissberg J, Berman BM. Effectiveness guidance document (EGD) for acupuncture research - a consensus document for conducting trials. BMC Complement Altern Med. 2012;12(1):148. doi 10.1189/1472-6882-12-148. PMID: 22953730

25. Chalkidou K, **Tunis SR**, Whicher D, Fowler R, Zwarenstein M. The role for pragmatic randomized controlled trials (pRCTs) in comparative effectiveness research. Clin Trials. 2012; 9(4): 436-446. doi:10.1177/1740774512450097. PMID: 22752634

26. Saag KG, Mohr PE, Esmail L, Wright N, Beukelman TG, Curtis JR, Cutter G, Delzell E, Gary LC, Harrington TM, Karkare SU, Kilgore ML, Lewis CE, Moloney RM, Mudano AS, Oliveira A, Singh J, Warriner A, Zhang J, Berger M, Cummings SR, Pace W, Solomon DH, Wallace R, **Tunis SR**. Improving the efficiency and effectiveness of pragmatic clinical trials in older adults in the United States. Contemp Clin Trials. 2012;33(6) 1211-1216. doi: 10.1016/j.cct.2012.07.002

27. Witt CM , Manheimer E , Hammerschlag R , Lüdtke R , Lao L , et al. How well do randomized trials inform decision making: Systematic review using comparative effectiveness research measures on acupuncture for back pain? PLoS ONE. 2012;7(2): e32399. doi:10.1371/journal.pone.0032399.

28. Witt CM, Chesney M, Glicklich R, Breen L, Lewith G, Luce B, McCafferty A, Withers SR, Sox HC, **Tunis SR**, Berman BM. Building a strategic framework for comparative effectiveness research in complementary and Integrative Medicine. Evidence-Based Complementary and Alternative Medicine. 2012. (2012) Article ID 5311096 5 pages. doi:10.1155/2012/531096

29. Veenstra DL, Piper M, Haddow J, Pauker SG, Klein R, **Tunis, SR** et al. "Improving the efficiency and relevance of evidence-based recommendations in the era of whole-genome sequencing: An EGAPP methods update." Genet Med. 2012;15(1):14-24. doi: 10.1038/gim.2012.106. PMID: 22955111

30. Messner DA, **Tunis SR**. Current and Future State of FDA-CMS Parallel Reviews. Clin Pharmacol Ther. 2012;91(3), 383-385. doi:10.1038/clpt.2011.350. PMID: 22343814

31. Deverka PA, Lavallee DM, Desai PJ, et al. Stakeholder participation in comparative effectiveness research: Defining a framework for effective engagement. J Comp Effect Res. 2012;1(2), 181–194.

32. Chernew, M, Lakdawalla, DN, Berenson, R, Rubin, RJ, **Tunis, SR** et al. (2012) Independent payment advisory board working group: An expert view on the new health care legislature. Manuscript submitted for publication.

33. Ramsey SD, Veenstra D, **Tunis SR**, Garrison L, Crowley JJ, Baker LH. How comparative effectiveness research can help advance 'personalized medicine' in cancer treatment. Health Aff. 2011;30(12):2259-2268. doi: 10.377/hlthaff.2010.0637

34. Tiglao MR, Phurrough S, Mullins CD**,** Abernethy AP, **Tunis SR.** Development of effectiveness guidance documents (EGDs) as a stakeholder-driven process for informing study designs for comparative effectiveness research (CER). J Clin Oncol 29: 2011 (suppl: abstr e16617). Submission to ASCO.

35. **Tunis SR**, Berenson R, Phurrough S, Mohr PE. Improving the quality and efficiency of the Medicare program through coverage policy. Urban Institute 2011: http://www.urban.org/url.cfm?ID=412392

36. Dreyer NA, **Tunis SR**, Berger M et al. Why observational studies should be among the tools used in comparative effectiveness research. Health Aff. 2010; 29(10): 1818-1825.

37. Hoffman A, Montgomery R, Aubry WM, **Tunis SR**. How best to engage patients, doctors, and other stakeholders In designing comparative effectiveness studies. Health Aff. 2010; 29(10):1834-1841.

38. Menon D, McCabe CJ, Stafinski T, et al. Principles of design of access with evidence development approaches: A consensus statement from the Banff summit. Pharmacoeconomics. 2010;28(2):109-11. doi: 10.2165/11530860. PMID: 20085388

39. Mohr PE, **Tunis SR**. Access with evidence development: The US experience. Pharmacoeconomics. 2010;28(2):153-162. doi: 10.2165/11531050. PMID: 20085391

40. Mullins CD, Montgomery R, **Tunis SR**. Uncertainty in assessing value of oncology treatments. The Oncologist. 2010;15(s1):58-64. doi: 10.1634/theoncologist.2010-s1-58. PMID: 20237219

41. Mullins CD, Whicher D, Reese E, **Tunis SR**. Generating evidence for CER using pragmatic randomized clinical trials. Pharmacoeconomics. 2010;28(10):969-976. doi: 10.2165/11536160. PMID: 20831305

42. Neumann PJ, **Tunis SR**. Medicare and medical technology – the growing demand for relevant outcomes. N Engl J Med. 2010;236:377-379. doi:10.1056/NEJMp0912062

43. Schulman KA, **Tunis SR**. A policy approach to the development of molecular diagnostic tests. Nat Biotechnol. 2010; 28(11):1-3.

44. Mohr PE, **Tunis SR**, Sabharwal R, Montgomery R, Bergthold L. The comparative effectiveness research landscape in the United States and its relevance to the Medicare program. 2010. Baltimore, MD: Center for Medical Technology Policy.
45. **Tunis SR**, Benner J, et al. Response to comments on "Comparative Effectiveness Research". Stat Med. 2010; 29(19):1999-1997.

46. **Tunis SR**, Pearson SD. US moves to improve health decisions. BMJ. 2010;341:c3615. doi:10.1136/bmj.c3615.

47. Chalkidou K, **Tunis SR**, Lopert R, Rochaix L, et al. Comparative effectiveness research and evidence-based health policy: Experience from four countries. Milbank Quarterly. 2009;87(2):339-67.

48. Chalkidou K, Whicher D, Kary W, **Tunis SR**. Comparative effectiveness research priorities: Identifying critical gaps in evidence for clinical and health policy decision making. Int J Technol Assess Health Care. 2009;25(3):241-248.

49. Garber AM, **Tunis SR**. Does comparative-effectiveness research threaten personalized medicine? N Engl J Med. 2009; 360(19):1925-7.

50. Luce BR, Kramer JM, Goodman SN, Connor JT, **Tunis S**, Whicher D, & Schwartz JS. Rethinking randomized clinical trials for comparative effectiveness research: the need for transformational change. Ann Intern Med. 2009; 151(3):206-9. Epub 2009 Jun 30.

51. Thorpe KE, Zwarenstein M, Oxman AD, Treweek S, Furberg CD, Altman DG, **Tunis SR**, et al. A pragmatic-explanatory continuum indicator summary (PRECIS): A tool to help trial designers. J Clin Epidemiol. 2009;62(5):0(10):464-475. doi:10.1016/j.jclinepi.2008.12.001. PMID: 19348971

52. Thorpe KE, Zwarenstein M, Oxman AD, Treweek S, Furberg CD, Altman DG, **Tunis SR**, et al. A pragmatic-explanatory continuum indicator summary (PRECIS): A tool to help trial designers. CMAJ. 2009;180(10):E47-E57. doi: 10.1503/cmaj.090523. PMCID: PMC2679824

53. **Tunis SR**, Whicher D. The National Oncologic PET Registry: Lessons learned for coverage with evidence development. J Am Coll Radiol. 2009;6(5):360-365.

54. **Tunis SR**, Seidenfeld J. Decision-based evidence making: Developing tools and strategies for comparative effectiveness. Asian Hospital & Healthcare Management. 2009;19:11-16.

55. Whicher D, Chalkidou K, Dhalla IA, Levin L, **Tunis SR**. Comparative effectiveness research in Ontario, Canada: Producing relevant and timely information for health care decision makers. The Milbank Quarterly. 2009;87(3):585-606. doi: 10.1111/j.1468-0009.2009.00572.x

56. Douglas PS, Budoff M, **Tunis SR**, Woodard PK, Justman RA, Honigber R. A new era for cardiovascular imaging? Implications of the revoked national coverage decision for CT angiography on future imaging reimbursement. JACC Cardiovascular Imaging. 2008; 1(3):398-403.

57. O'Kane M, Corrigan J, Foote SM, **Tunis SR**, et al. Crossroads in quality. Health Aff(Millwood). 2008; 27(3):749-58.

58. Zwarenstein M, Treweek S, Gagnier JJ, Altman DG, **Tunis SR**. Improving the reporting of pragmatic trials: An extension of the CONSORT statement. BMJ. 2008;337:a2390.

59. **Tunis SR**, Chalkidou K. Coverage with evidence development: A very good beginning, but much to be done. Commentary to Hutton et al. Int J Technol Assess Health Care. 2007; 23(4):432-435. doi: 10.1017.S0266462307070614. PMID:17937830

60. Elshaug AG, Hiller JE, **Tunis SR**, Moss JR. Challenges in Australian policy processes for disinvestment from existing, ineffective health care practices. Aust New Zealand Health Policy. 2007;4:23. doi:10.1186/1743-8462-4-23. PMCID: MPC2174492

61. Lindsay MJ, Seigel BA, **Tunis SR**, et al. The National oncologic PET registry: Expanded Medicare coverage for PET under coverage with evidence development. AJR Am J Roentgenol. 2007;188(4):1109-13.

62. Lynn J, Baily MA, Bottrell M, Jennings B, et al. The Ethics of Using Quality Improvement Methods in Health Care. Ann Inten Med. 2007;146(9): 666-673.

63. **Tunis SR**. Reflections on science, judgment, and value in evidence-based decision making: A conversation with David Eddy. Health Aff. 2007;26(4): w500-w515.

64. **Tunis SR**, Carino TV, Williams RD 2nd, Bach PB. Federal initiatives to support rapid learning about new technologies. Health Aff(Millwood). 2007;26(2):w140-9.

65. **Tunis SR** and Pearson SD. Coverage Options for Promising Technologies: Medicare's 'coverage with evidence development'. Health Aff. 2006; 25(5):1218-1230.

66. Woolf SJ, Chan ECY, Harris R, Sheridan SL, Braddock CH, Kaplan RM, Krist A, O'Connor AM, **Tunis SR**. Promoting informed choice: transforming healthcare to dispense knowledge for decision making. Ann Internal Med. 2005;143(4):293-300.

67. Majumdar SR, Ross-Degnan D, Farraye FA, Lee M, Kemp JA, LeCates RF, Henning JA, **Tunis SR**, Schrammel P, Soumerai SB. Controlled trial of interventions to increase testing and treatment for helicobacter pylori and reduce medication use in patients with chronic acid-related symptoms. Aliment Pharmacol Ther. 2005;21(8):1029-1039.
68. **Tunis SR**. A Clinical Research Strategy To Support Shared Decision Making. Health Aff. 2005;24:180-184. PMID: 15647229

69. McClellan MB, **Tunis SR**. Implantable cardioverter-defibrillators. N Engl J Med. 2005;352:2025. [letter].

70. McClellan MB, **Tunis SR**. Medicare coverage of ICDs. N Engl J Med. 2005;352:222-224.

71. **Tunis SR**. Medicare coverage for technological innovations. N Engl J Med. 2004;351:720. [letter].

72. **Tunis SR**. Why Medicare has not established criteria for coverage decisions. N Engl J Med. 2004;350:2196-2198.

73. **Tunis SR**. Economic analysis in healthcare decisions. Amer J Manag Care. 2004;10:301-304.

74. Carino T, Sheingold S, **Tunis S**. Using clinical trials as a condition of coverage. Lessons from the National Emphysema Treatment Trial. Clin Trials 2004;1:1-14.

75. Kessler L, Ramsey SD, **Tunis S**, Sullivan S. Clinical use of medical devices in the "Bermuda Triangle" between CMS, FDA and NIH. Health Aff (Millwood.) 2004;23(1):200-207.

76. **Tunis SR**, Stryer DB, Clancy CM. Practical clinical trials: Increasing the value of clinical research for decision making in clinical and health policy. JAMA 2003:290:1624-1632.

77. **Tunis SR**, Kang JL. Improvements in Medicare coverage of new technology. Health Aff (Millwood). 2001;20:83-85.

78. **Tunis SR**, Sheinhait MA, Schmid C, Bishop BA, Ross SD. The efficacy of lansprozole compared to histamine-2 receptor antagonists in healing gastric ulcers: A meta-analysis. Clin Therap 1997:19(4):743-757.

79. Hayward RSA, Wilson, MC, **Tunis SR**, Guyatt GH. Practice guidelines: What are internists looking for? J Gen Intern Med 1996:11:176-178.

80. Weingarten S, Stone E, Hayward R, **Tunis S**. The adoption of preventive care practice guidelines by primary care physicians: Do actions match intentions? J Gen Intern Med 1995: 10(3):138-44.

81. Steinberg EP, **Tunis S**, Shapiro D. Insurance coverage for experimental technology. Health Aff. 1995: Winter: 143-158.

82. Oxman AD, Sackett DL, Guyatt GH; for the Evidence-Based Medicine Working Group. Users' Guides to the Medical Literature: I. How to get started, JAMA. 1993;270: 2093-2095. [**S Tunis** listed as a contributor to this article.]

83. Oxman AD, Cook DJ, Guyatt GH; for Evidence-Based Medicine Working Group. Users' Guides to the Medical Literature. VI. How to use an Overview. JAMA. 1994; 272: 1367-1371. [**S Tunis** listed as a contributor to this article.]

84. Levine M, Walter S, Lee H, Haines T, Holbrook A, Moyer V; for the Evidence-Based Medicine Working Group. Users' Guides to the Medical Literature. IV. How to use an article about harm. JAMA. 1994; 271: 1615-1619. [**S Tunis** listed as a contributor to this article.]

85. Jaeschke R, Guyatt G, Sackett DL; for the Evidence-Based Medicine Working Group. Users' Guides to the Medical Literature. III. How to use an article about a diagnostic test. B. What are the results and will they help me in caring for my patients? JAMA. 1994;271: 703-707. [**S Tunis** listed as a contributor to this article.]

86. Jaeschke R, Guyatt G, Sackett DL; for the Evidence-Based Medicine Working Group. Users' Guides to the Medical Literature: III. How to use an article about a diagnostic test. A. Are the results of the study valid? JAMA. 1994;271: 389-391. [**S Tunis** listed as a contributor to this article.]

87. Guyatt GH, Sackett DL, Cook DJ; for the Evidence-Based Medicine Working Group. Users' Guides to the Medical Literature: II. How to use an article about therapy or prevention. B. What were the results and will they help me in caring for my patients? JAMA. 1994;271: 59-63. [**S Tunis** listed as a contributor to this article.]

88. Guyatt GH, Sackett DL, Cook, DJ; for the Evidence-Based Medicine Working Group. Users' Guides to the Medical Literature: II. How to use an article about therapy or prevention. A. Are the results of the study valid? JAMA. 1993; 270-2598-2601. [**S Tunis** listed as a contributor to this article.]

89. Rubin HR, Wu AW, **Tunis S**. Warning – Inhaling tabasco products can be hazardous to your health. W Journal Med, 1994 [letter].

90. Wilson MC, Hayward RSA, **Tunis SR**, Bass EB, Guyatt G. Users' guides to the medical literature: VIII. How to use clinical practice guidelines. B. What are the recommendations and will they help you in caring for your patients. JAMA 1995: 274(20):1630-1632.

91. Hayward RSA, Wilson MC, **Tunis SR**, Bass EB, Guyatt G. Users' guides to the medical literature: VIII. How to use clinical practice guidelines. A. Are the recommendations valid. JAMA 1995:274:570-574.

92. Wilson MC, Tunis SR, Hayward RSA, Kern DE, Howard DM, Bass EB. Primary care physicians' attitudes toward clinical practice guidelines. J Gen Intern Med. 1993: 6:114-118.

93. **Tunis SR**, Wilson MC, Hayward RSA, Rubin HR, Bass EB, Steinberg EP. Internists' attitudes toward clinical practice guidelines. Ann of Intern Med. 1994;120:956-963.

94. **Tunis SR**, Hayward RSA, Wilson MC. Attitudes about guidelines. Ann Int Med 1994:121(9):725-6 [letter].

95. Steinberg EP, Bass EB, **Tunis SR**. Interventional management of peripheral vascular disease: what did we learn in Maryland and where do we go from here? Radiology. 1993;186:639-642.

96. Hayward RSA, Wilson MC, **Tunis SR**, Bass EB, Haynes RB. More informative abstracts of articles describing clinical practice guidelines. Ann Intern Med. 1993;118:731-737.

97. **Tunis SR**, Bass EB, Klag MJ, Steinberg EP. Variation in utilization of procedures used for treatment of peripheral arterial disease: a look at patient characteristics. Arch Int Med. 1993;153:991-998.

98. **Tunis SR**, Bass EB, Steinberg EP. The use of angioplasty, bypass surgery, and amputation in the management of peripheral vascular disease. N Engl J Med. 1991 [letter].

99. **Tunis SR**, Bass EB, Steinberg EP. The use of angioplasty, bypass surgery, and amputation in the management of peripheral vascular disease. N Engl J Med. 1991;325:556-562.

100. Showstack J, Garnick D, Rosenfeld K, Luft H, Shaffarzick R, **Tunis S**, Fowles J. Episode-of-care physician payment: a study of coronary artery bypass graft surgery. Inquiry. 1987;24:376-383.

PEER-REVIEWED REPORTS PRODUCED AS DIRECTOR OF THE HEALTH PROGRAM, CONGRESSIONAL OFFICE OF TECHNOLOGY ASSESSMENT

1. Health Care Technology and Its Assessment in Eight Countries (February 1995)

2. The Cost-Effectiveness of Colorectal Cancer Screening in Average-Risk Adults (April 1995)

3. Costs and Effectiveness of Prostate Cancer Screening in Elderly Men (May 1995)

4. Hospital Financing in Seven Countries (May 1995)

5. Coverage of Laser Technology by Health Insurers (August 1995)

6. Effectiveness and Costs of Osteoporosis Screening and Hormone Replacement Therapy, Vol. I: Cost-Effectiveness Analysis (August 1995)

7. Effectiveness and Costs of Osteoporosis Screening and Hormone Replacement Therapy, Vol. II: Evidence on Benefits, Risks, and Costs (August 1995)

8. Adverse Reactions to HIV Vaccines: Medical, Ethical, and Legal Issues (September 1995)

9. Bring Health Care Online: The Role of Information Technologies (September 1995)

10. The Effectiveness of AIDS Prevention Efforts (September 1995)

11. Impact of Health Reform on Rural Areas: Lessons from the States (September 1995)

12. Impacts of Antibiotic-Resistant Bacteria (September 1995)

13. Psychiatric Disabilities, Employment and the Americans with Disabilities Act (March 1994)

14. Understanding Estimates of National Health Expenditures Under Health Reform (May 1994)

15. Defensive Medicine and Medical Malpractice (July 1994)

16. Managed Care and Competitive Health Care Markets: The Twin Cities Experience (July 1994)

17. Understanding Estimates of the Impact of Health Reform on the Federal Budget (July 1994)

18. The Department of Defense Kuwait Oil Health Fire Risk Assessment (The "Persian Gulf Veterans' Registry") (September 1994)

19. External Review of the Federal Centers for Disease Control and Prevention's HIV Prevention Program: Summary and Overview (September 1994)

20. Hip Fracture Outcomes in People Age 50 and Over (September 1994)
21. Identifying Health Technologies that Work: Searching for Evidence (September 1994)

22. International Comparisons of Administrative Costs in Health Care (September 1994)

23. Internal Health Statistics: What the Numbers Mean for the United States (September 1994)

24. Mental Disorders and Genetics: Bridging the Gap between Research and Society (September 1994)

25. Public Information About Osteoporosis: What's Available, What's Needed? (September 1994)

26. Review of the Medical Follow-Up Agency (September 1994)

27. Tools for Evaluating Health Technologies: Five Background Papers (Patient reported data, Large administrative databases, Simple randomized trials, Meta-analysis, Clinical-economic trials (September 1994)

28. Universal Health Insurance and Uninsured People: Effects on Use and Cost (September 1994)

BOOK CHAPTERS

1. Powe N, **Tunis SR**. Clinical Practice Guidelines, in T Gordon and Cameron. Evidence-based Surgery.

2. **Tunis SR**. Beyond randomized trials: new partnerships in effectiveness research, in Outcomes and Effectiveness Research 1998. Faulkner & Gray, New York. 1998.

3. Mathias SM, **Tunis SR**. Quality of Life Measurement in Managed Care Research, in Research in Managed Care. Parexcel. San Francisco, 1998.

4. **Tunis SR**. Government Involvement in Guidelines in JE Casanova, ed. Tools for the task: the role of clinical guidelines. Pp 39-54 (chapter 4). American College of Physician Executives, Tampa. 1997.

5. J.L. Wagner, **S. Tunis**, M. Brown, A. Ching, R. Almeida, Cost-effectiveness of Colorectal Cancer Screening in Average-Risk Adults, in G.P. Young, Paul Rozen and B. Levin, eds. Prevention and Early Detection of Colorectal Cancer. Pp. 357-368 (chapter 19) W.B. Saunders Company Lts., London, 1996.

6. Hayward RSA, Wilson MC, **Tunis SR**. Locating clinical practice guidelines. In: Vibbert S, Reichard J, eds. The medical outcomes and guidelines sourcebook. New York: Faulkner & Gray; 1992:223-32.

SELECTED WORKSHOPS / PANELS

1. Presenter. Scenario Design Session – Design Discussion. New Drug Development Paradigms Initiative (NEWDIGS) Q3 Working Sessions Workshop. MIT. Cambridge, MA. September 16, 2013.

2. Panel presenter. Diagnostics Industry Vision 2020: Evidence & Patient-Centered Outcomes. 5th Annual Diagnostics Summit. California Institute of Health and Illumina. San Diego, CA. September 12, 2013.

3. Panel presenter. Outcomes work from other groups and perspectives. Core Outcomes Measures in Effectiveness Trials (COMET) Initiative. Manchester England. June 20, 2013.

4. Panel presentation. Implications for Health Systems and Industry. PharmaFutures Global Report. Meteos. London, UK. June 19, 2013.

5. Panel presenter. Reimbursement and Payer Panel. The Business of Personalized Medicine Summit: Advancing Industry Innovation into Commercial Success. San Francisco, CA. May 13-15, 2013.

6. Panel moderator. The Need for New and Comprehensive Models for Evidence Development. 9th Annual Post Approval Summit. Outcomes. Boston, MA. May 7, 2013.

7. Panel discussion. Definition of Value and Payer Perception. 3rd Party Payers for Alzheimer's Treatment and Diagnosis Research Roundtable. Alzheimer's Association. Washington, DC. April 15, 2013.

8. Podium presentation. Ethical Framework for the Learning Health System. Institute of Medicine. Washington, DC. March 28, 2013.

9. Panel coordinator. Biomedical Technologies. National Health Research Policy Dialogue: Mobilizing Science and Technology to Lower Costs and Improve Outcomes. Executive Office of the President of the United States and Stanford University, School of Medicine – Clinical Excellence Research Center. Palo Alto, CA. January 15 – 16, 2013.

10. Panel presentation. Review of what domains matter to payers. Psoriasis Outcomes Measures (POM) Project Meeting. Psoriasis Foundation. Boston, MA. January 5, 2013.

11. "PROs and the challenge of quality cancer care." Millennium Cancer Advocacy Council. Takeda Millennium. Cambridge, MA. January 9, 2013.

12. Global Health Technology Assessment Advisory Board Meeting. Merck. Boston, MA. November 12 – 13, 2012.

13. Comparative Effectiveness Research (CER) Workshop Sanofi. Boston, MA. September 21, 2012.

14. Comparative Effectiveness Research (CER) Workshop Sanofi. Paris, France. September 18, 2012.

15. Electronic Data Systems/ HER Workshop. Patient-Centered Outcomes Research Institute (PCORI). Palo Alto, CA. July 2 – 3, 2012.

16. North America HTA Council Meeting. Sanofi. Cambridge, MA. June 14, 2012.

17. EGAPP Working Group Meeting. Atlanta, GA. January 30 – 31, 2012.

18. Breakout session. Aligning HTA methods and practices with other health system processes or stakeholder groups. HTAi Policy Forum. Health Technology Assessment International. San Francisco, CA. January 21 – 26, 2012.

19. Putting the Research into Comparative Effectiveness Research. International Conference on Health Policy Statistics. Washington, DC. January 22, 2010.

20. Using the GRADE system to appraise evidence for health systems interventions. World Health Organization. Geneva, Switzerland. December 15, 2009.

21. Panel presentation. Synthesis of Infrastructure Components from the Use Cases: Methods. Strategic Goal Committee 4 Annual In-Person Meeting. Clinical Translational Science Awards (CTSA) PCTi Workshop. Bethesda, MD. November 19, 2012.

22. Mock panel presentation. Are we on the right track to deliver value to HTA/Payers? Challenges and potential solutions with practical project examples. Bayer CER Workshop. Berlin, Germany. November 9, 2012.

23. Panel speaker. Designing CER Studies that Reflect the Perspective of Patients, Clinicians, and Payers. Oregon Institute for Patient-Centered Comparative Effectiveness Annual Research Intensive. Portland, OR. October 18, 2012.

24. Panel session. Rationale and History of the Green Park Collaborative. Health Technology Assessment International (HTAi) Annual Meeting 2012. Bilbao, Spain. June 25, 2012.

25. Issue panel. Cutting the Fog: Have We Reached Clarity on Diagnostics and Personalized Medicine Evidence Expectations? 17th Annual International Meeting. ISPOR. Washington, DC. June 6, 2012.

26. Issue panel. Accelerating the Development of Comparative Effectiveness Information: Does Phase 3B Represent an Opportunity? 17th Annual International Meeting. ISPOR. Washington, DC. June 5, 2012.

27. Panel moderator. Will CER Stimulate or Depress Innovation in Health Care? 17th Annual International Meeting. ISPOR. Washington, DC. June 4, 2012.

28. Health Technology Assessment for Pharmaceuticals. Advisory group for Sanofi-Aventis. Paris, France. November 3, 2009.

29. Invited expert reactor. Project on Reforming Traditional Medicare. Stanford University School of Medicine and Business. Palo Alto, CA. October 18, 2006.

30. Co-chair. Workshop on Comparative Effectiveness Research. IOM. November 15, 2004.
31. National Commission on Prevention Priorities. Partnership for Prevention. 2003, 2004.

32. Blue Ribbon Committee on Invasive Surgical Trials. Veterans Administration. Washington DC. March 31, 2003.

33. Workshop on Clinical Research Priorities for Payers. Institute of Medicine Clinical Research Roundtable. Washington DC. December 16, 2002.

PRESENTATIONS

1. Participant. MaRS excellence in Clinical Innovation and Technology Evaluation (EXCITE). MaRS Discovery District. Toronto, Ontario, Canada. August 15, 2013.

2. Presenter. Value and Innovation: What Will the New Day Look Like for Patients? FasterCures and The Cystic Fibrosis Foundation. Washington, DC. July 9,2013.

3. Presenter. Do You See What I See? Roundtable on Acceptenace and Concordance of Observational Studies. National Pharmaceutical Council and The Lewin Group. Washington, DC. June 27, 2013.

4. Invited plenary speaker. Evidence. HTAi 2013 meeting. Seoul, Korea. June 17, 2013.

5. Presenter. Comparative Effectiveness Research and the Future of Clinical Development. Boehringer Ingelheim President's Council. Cambridge, MA. June 13, 2013.

6. Presenter. Guidelines: How are they formed? What are the general critques? Johns Hopkins EBM Forum. Baltimore, MD. June 5, 2013.

7. Invited speaker. Shifting Role of Pragmatic Clinical Trials in Effectiveness Research. 9th Annual Post Approval Summit. Outcomes. Boston, MA. May 7, 2013.

8. Invited speaker. A Collaborative Process to Define Evidence Standards for the Clinical Utility of Molecular Diagnostics. Genomic and Personalized Medicine Forum. Duke University – Institute for Genome Sciences & Policy. Durham, NC. April 25, 2013.

9. Invited speaker. Public and Private payer Guidance for Studies of Alzheimer's Drug Treatments. 3rd Party Payers for Alzheimer's Treatment and Diagnosis Research Roundtable. Alzheimer's Association. Washington, DC. April 15, 2013.

10. Podium presentation. A Collaborative Process to Define Evidence Standards for the Clinical Utility of Molecular Diagnostics. Next Generation Sequencing Summit. Palmetto GBA. Baltimore, MD. March 26, 2013.

11. Invited speaker. Payers Perspectives on More Informative Clinical Trials. Johns Hopkins University Causal Inference Seminar. Baltimore, MD. February 26, 2013.

12. Invited speaker. The Role of CER within Pharmaceutical Development Focusing in Pragmatic Studies. Comparative Effectiveness Research (CER) Symposium: Maximizing the Use of CER for Product Development and Commercialization. Boehringer Ingelheim Pharmaceuticals, Inc. Ridgefield, CT. December 10, 2012.

13. Podium presentation. Molecular diagnostics: Turning on the lights. Partnering for Cures – FasterCures. New York, NY. November 30, 2012

14. Invited speaker. American Society of Clinical Oncology (ASCO). Alexandria, VA. November 27, 2012.

15. Plenary speaker. Research in Comparative Effectiveness. Life Science Tennessee Annual Meeting. Mountain Group Capital, LLC. Nashville, TN. November 15, 2012.

16. Podium presentation. Demonstrating the added clinical value: How HTA/Payers assess clinical data beyond regulatory assessments. Bayer CER Workshop. Berlin, Germany. November 9, 2012.

17. Podium presentation. Using CED to Lower Costs and Improve Outcomes in Medicare. 4th National Comparative Effectiveness Summit. Washington, DC. November 6, 2012.

18. Invited speaker. Merck & Co., Inc. North Wales, PA October 26, 2012.

19. Podium presentation. Genomics, Reimbursement, and the Clinical Utility "Problem". Reimbursement Models to Promote Evidence Generation and Innovation for Genomic Tests Workshop Center for Medical Technology Policy, Inc. (CMTP) and NHGRI. Bethesda, MD. October 24, 2012.

20. Podium presentation. Introduction to Coordinating Center Expertise: Stakeholder Engagement. Research Collaboratory Steering Committee Meeting. National Institutes of Health (NIH). Rockville, MD. October 23, 2012.

21. Podium Presentation. Collaborations to Develop HTA Regulatory Guidance: The Green Park Collaborative. 3rd DIA Health Technology Assessment (HTA) Forum – Regulatory and HTA Interface Developments. Amsterdam, the Netherlands. September 14, 2012.

22. Discussion leader. Developing Guidance from HTA and Coverage Bodies to Inform Clinical Trial Design: The Green Park Collaborative. 17th Annual International Meeting. ISPOR. Washington, DC. June 5, 2012.

23. Plenary session moderator. Comparing the Effectiveness of New Drugs: Should the FDA be asking 'Does It Work' or 'Does It Work Better'? 17th Annual International Meeting. ISPOR. Washington, DC. June 4, 2012.

24. Invited session. Comparative Effectiveness and Costly New Drugs. 2012 American Society of Clinical Oncology (ASCO) Annual Meeting. Chicago, IL. June 2, 2012.

25. Invited session. Confusions and Controversies around Pragmatic Trials. 2012 Society for Clinical Trials (SCT) Meeting. Miami, FL. May 21, 2012.

26. Plenary session. Introducing the involvement of stakeholders as an important aspect of CER in the context of Integrative Health: The Relevance of Stakeholder Perspectives for CER on Integrative Health. 2012 International Research Congress on Integrative Medicine & Health (IRCIMH) Meeting. Portland, OR. May 17, 2012

27. Podium presentation. Implementing Genomic Medicine Programs – Standards. 3rd Genomic Medicine Centers: Working with Implementation Stakeholders. Chicago, IL. May 3, 2012.

28. Panel moderator. How will Patient-centered Comparative Effectiveness Research impact patient access to innovative medical products? National Venture Capital Association Annual Life Science Meeting. Santa Clara, CA. April 24, 2012.

29. Issue panel. Perspectives on challenges, opportunities, and future directions. Symposium on Comparative Effectiveness of Advanced Imaging in Cancer: Accomplishments, Challenges, and Opportunities. Boston, MA. April 30, 2012.

30. Plenary speaker. Pharmaceutical Policy in Canada: Do We Have the Right Prescription? 2012 CADTH Symposium. Ottawa, Canada. April 17, 2012.

31. Podium presentation. Developing HTA Regulatory Guidance Documents. 24th Annual DIA EuroMeeting. Copenhagen, Denmark. March 27, 2012.

32. Keynote address. Defining High Value Health Care through Comparative Effectiveness Research. Mid- Atlantic SGIM 2012 Regional Meeting. Newark, DE. March 16, 2012.

33. Podium presentation. Development of a guidance for including patient-reported outcomes (PROs) in post-approval clinical trials of oncology drugs for comparative effectiveness research (CER). 16th Annual International Meeting, ISPOR. Baltimore, MD. May 21-25, 2011.

34. Issue panel. Is FDA/CMS parallel review worthwhile? Is it feasible? 16th Annual International Meeting, ISPOR. Baltimore, MD. May 21-25, 2011.

35. Plenary speaker. National Cancer Institute, Comparative Effectiveness Research GO Grantee meeting. Rockville, MD. January 5, 2010.

36. Plenary speaker. National Pharmaceutical Council town hall meeting on CER. Wilmington, DE. December 10, 2009.

37. Keynote speaker. Major Extremity Trauma Research Consortium steering group meeting. Baltimore, MD. December 7, 2009.

38. Speaker. International Perspectives in Health Technology Assessment. Annual meeting of the National Institute of Clinical Effectiveness. Manchester, UK. Dec 2, 2009.

39. Invited expert. Policy-Informed Research: Improving evidence for decision making in health systems interventions. World Health Organization. Geneva, Switzerland. Nov 27, 2009.

40. Keynote speaker. Improving Evidence in Health Care Decision Making for Oncology. Annual meeting of US Oncology. Chicago, IL. November 13, 2009

41. Seminar presenter. Pragmatic Clinical Trials. Johns Hopkins Center for Clinical Trials. Baltimore, MD. November 11, 2009.

42. Keynote speaker. Improving the quality of medical device trials. Annual meeting of the Medical Device Manufacturers Association. Washington, DC. Nov. 10, 2009

43. Panel session speaker. Improving research in radiation oncology. Annual meeting of the American Society of Radiation Oncology (ASTRO). Chicago, IL. Nov 1, 2009.

44. Speaker. Post-marketing Evaluation: Reimbursement Considerations. Cardiovascular Revascurization Therapy 2008. Washington, DC. February 13, 2008.

45. Lead Faculty. Comparative Effectiveness Research for Policy Professionals. AcademyHealth National 2008 Health Policy Conference. Washington, DC. February 6, 2008.

46. Panel Member. Institute of Medicine Workshop on Diffusion and Use of Genomic Innovations in Health and Medicine. Washington DC. December 4, 2007.

47. An Overview of Comparative Effectiveness Research. Brandeis Health Industry Forum, America's Health Insurance Plans, Kaiser and Merck. Technology Assessment Roundtable. Washington DC. November 30, 2006.

48. Product development – How to build reimbursement value into your biotech asset. BIO Investors Forum. San Francisco, CA. October 19, 2006.

49. Decoding CMS and Working with Payers: Laguna Niguel Biotech Summit. Laguna Beach, CA. October 9, 2006.

50. Reimbursement for FDG-PET in the United States. Academy of Molecular Imaging PET/CT Symposium. Athens, Greece. September 29, 2006.

51. Improving Evidence for Healthcare Decisions. Alliance for Healthcare Reform Capitol Hill briefing. Washington, DC. September 22, 2006.

52. Implications of Trends in Drug Pricing for the Biotech Industry: Atlas Ventures retreat. Nice, France. September 17, 2006.

53. Reimbursement Strategy for Early-Stage Life Sciences Companies. National Venture Capital Association Workshop. Waltham, MA. September 13, 2006.

54. A Practical Clinical Trial of FDG-PET for Suspected Dementia: Institute of Medicine workshop on The Learning Healthcare System. Washington, DC. July 20, 2006.

55. Evidence-Based Policy in Oncology. ASCO/SGO 8th annual meeting of Hematology/Oncology Carrier Advisory Committee Network. Landsdowne, VA. July 14, 2006.

56. Technology and Rising Health Care Spending. AcademyHealth annual research meeting. Seattle, WA. June 26, 2006.

57. Should there be a NICE in the US? ISPOR. Philadelphia, PA. May 23, 2006.

58. Reimbursement Strategy for Early Stage Life Sciences Companies. BIOCOM: CalBIO 2006. San Diego, CA. May 18, 2006.

59. New Partnerships: Redefining the Clinical Research Enterprise. Avalere Health conference on Evidence-based Medicine. Washington, DC. May 9, 2006.

60. Medical Management Systems Innovations: The Next Generation. American Board of Quality Assurance and Utilization Review Physicians. Orlando, FL. May 5, 2006.

61. Expert Panelist. Can the Life Sciences Industry Change Washington's Perspective on the Cost and Benefit of Medical Innovation and Improve Public Policy Outcomes? National Venture Capital Association, annual meeting. San Jose, CA. April 26, 2006.

62. Expert Panelist, Gaps between knowledge and application. American College of Clinical Pharmacy. Sprint Practice and Research Forum. Monterey, CA. April 10, 2006.

63. Keynote Speaker, Translating Research into Practice. American College of Clinical Pharmacy. Sprint Practice and Research Forum. Monterey, CA. April 9, 2006.

64. International Guest Speaker. Stealth economics: case studies from US Medicare. National Health Service Managers Retreat. Oxford, UK. March 23, 2006.

65. Author / Presenter: Federal initiatives to support rapid learning about new technologies. Rapid Learning in Healthcare (Robert Wood Johnson Foundation project). Washington, DC. March 17, 2006.

66. Panel Speaker, Mind the gap: Improving evidence for healthcare decisions. American Association for the Advancement of Science Annual Meeting. St. Louis, MO. February 19, 2006.

67. Methods for improving evidence for healthcare decisions. Duke Clinical Research Institute. Durham, NC. February 7, 2006.

68. Plenary Session Speaker. Medicare coverage of molecular diagnostics. UCSF Breast Oncology Program 2006 Scientific Retreat. San Francisco, CA. January 24, 2006.

69. Mass Biotech Council. January 19, 2006.

70. Conference Speaker. Improving evidence for value-based payment for new medical technology. Center for Value-based Insurance Design, University of Michigan. Ann Arbor, MI. December 15, 2005.

71. Keynote Speaker. Practical clinical trials: methods and policy issues. CDC workshop on pharmacogenomic testing. Seattle, WA. December 14, 2005.

72. Keynote Speaker. Management of new medical technology. Integrated Healthcare Association. New Technology. San Francisco, CA. November 17, 2005

73. Expert Panelist. Public attitudes about new medical technology. Kaiser Institute for Health Policy Studies. San Francisco, CA. November 10, 2006

74. Visiting Faculty. Brandeis University. Boston, MA. June 15, 2005.

75. Plenary Speaker. The role of HMOs in clinical research. Building Bridges: HMO Research Network. Santa Fe, NM. April 5, 2005.

76. Session Chair. Improving evidence for decisions: the role of Medicare. Health Industry Forum. Washington, DC. April 1, 2005.

77. Keynote Speaker. Coverage with evidence development: public and private payer perspectives. J&J senior executive strategic planning retreat. New Brunswick, NJ. March 29, 2005.

78. Technology policy at CMS. Washington Policy Week for 4th year medical students. University of Virginia. March 11, 2005.

79. Keynote Speaker. Getting better value for health care spending. National Managed Health Care Congress. Washington, DC. March 8, 2005.

80. Featured Speaker. A clinical research strategy for shared decision making. Medical Technology Leadership Forum. Washington, DC. February 17, 2005.

81. Visiting Professor. Medicare and Medical Technology Policy. Leonard Davis Institute. Philadelphia, PA. February 11, 2005.

82. Keynote Speaker. The role of payers in clinical research. Chief Medical Officer Summit, American Health Insurance Plans. Santa Fe, NM. February 2, 2005.

83. Guest Professor. Medicare and pragmatic clinical trials. Ontario Ministry of Health and the University of Toronto. Toronto, Ontario, Canada. January 19, 2005.

84. Educational Session Panelist. AMA House of Delegates meeting. Pay-for-performance: The good, the bad and the ugly. Atlanta, GA. December 4, 2004.

85. Keynote Speaker. Georgia Life Sciences Summit. Biomedical innovation, biotechnology and reimbursement policy. Atlanta, GA. September 22, 2004.

86. Speaker. Biotechnology Industry Organization annual meeting. Cost-effectiveness of therapeutic products: What role in governmental policy? San Francisco, CA. June 7, 2004.

87. Session Chair. AcademyHealth Annual meeting. How much, how soon? Coverage decisions in the Medicare program. San Diego, CA. June 6, 2004.

88. Featured Guest. Hearth Rhythm Society annual meeting. A conversation with CMS regarding coverage of implantable cardiac devices. San Francisco, CA. May 21, 2004.

89. Keynote Speaker. American Heart Association 5th Scientific Forum on Quality of Care and Outcomes Research. Allocating expensive technologies. Washington, DC. May 16, 2004.

90. Panelist. V2 Biotech Summit. Impact of Healthcare Economics on Biotech Industry. San Jose, CA. April 22, 2004.

91. Plenary Speaker. Merrill Lynch Medical Technology University. Medicare Reimbursement New York, NY. December 4, 2003.

92. Plenary Speaker. 4th Annual Health Legacy Conference. Medicare Tools to Improve Quality of Care. Washington, DC. October 22, 2003.

93. Featured Speaker. BCBSA Medical Advisory Panel Discussion. Cost-effectiveness analysis in health care policy. Chicago, IL. October 14, 2003.

94. Core Faculty. ACC Santa Fe Cardiology CME. Reimbursement for Cardiac Rhythm Management. Santa Fe, NM. October 1-3, 2003.

95. Faculty. Morgan Stanley Investor Conference on Cardiac Rhythm Management. New York, NY. September 12, 2003.

96. Featured Speaker. The Quality Colloquium at Harvard University. CMS Tools for Quality Measurement and Improvement. Boston, MA. August 25, 2003.

97. Featured Speaker. Institute of Medicine symposium on Cancer Prevention. Medicare and Prevention: Challenges and Opportunities. Washington, DC. June 30, 2003.

98. Keynote Speaker. Medical Technology Leadership Forum. The Continuum from Experimental to Clinical Use: Alternative Models. Minneapolis, MN. July 17, 2003.

99. Keynote Speaker. North American Society for Pacing and Electrophysiology. How CMS views current issues in EP and pacing coverage. Washington, DC. May 15, 2003.

100. Keynote session speaker. American Health Lawyers Association meeting. New Technology Coverage and Payment. Baltimore, Maryland. April 3, 2003. ACC Annual Meeting, Chicago, IL.

101. Invited Presenter: Payment Issues Regarding Breast Cancer Imaging. IOM workshop panel on breast cancer detection. Washington, DC. March 25, 2003.

102. Keynote Speaker. Medicare and Medical Technology 2003. AdvaMed annual meeting. Aventura, FL. March 22, 2003.

103. Keynote Speaker. Medical Technology Leadership Forum. Medicare Coverage and Payment Policy. Washington, DC. January 30, 2003.

104. Featured Speaker. National Institute of Health Care Management. Accelerating Evidence-based Innovation: The Federal Role. Washington DC. January 27, 2003.

105. Panelist. National Health Policy Forum. Intro to Medicare for Congressional Staff. Overview of Medicare Coverage Decisions. Washington DC. January 24, 2003.

106. Guest Speaker. Stanford University Faculty Club. Venture Capital, Innovation and Reimbursement Policy. Palo Alto, CA. November 21, 2002.

107. Keynote Speaker. ECRI Annual conference: Coverage Decision Making by State and Federal Payers. Philadelphia, PA. October 30, 2002.

108. Invited Speaker. Indiana Medical Device Manufacturers Consortium. FDA-CMS Harmonization. Indianapolis, IN. October 11, 2002.

109. Visiting Professor. Medicare Reimbursement Policy. University of Michigan Department of Medicine and School of Public Health. Ann Arbor, MI. October 1-3, 2002.

110. Plenary Speaker. Clinical Trials Summit. Medicare Policy and Clinical Trials. Sponsored by AAHP / ECRI. Washington, DC. September 13, 2002.

111. Panel Member. Reimbursement Policy and Medical Technology Development. Medicare Payment Advisory Commission. Washington, DC. September 11, 2002

112. Plenary Session Speaker. Challenges in Designing Trials of Drug-Eluting Stents. Duke Clinical Research Institute. Mclean, VA. July 29, 2002.

113. Panel Member. Medicare Coverage Policy: The Balance between Local and National Decision Making. Medical Technology Leadership Forum. Washington, DC. June 28, 2002.

Committee on Energy and Commerce
U.S. House of Representatives

Witness Disclosure Requirement - "Truth in Testimony"
Required by House Rule XI, Clause 2(g)

1.	**Your Name:** Sean R. Tunis, MD, MSc		
2.	**Are you testifying on behalf of the Federal, or a State or local government entity?**	**Yes**	**No** X
3.	**Are you testifying on behalf of an entity that is not a government entity?**	**Yes**	**No** X
4.	**Other than yourself, please list which entity or entities you are representing:** NONE		
5.	**Please list any Federal grants or contracts (including subgrants or subcontracts) that you or the entity you represent have received on or after October 1, 2011:** NONE		
6.	**If your answer to the question in item 3 in this form is "yes," please describe your position or representational capacity with the entity or entities you are representing:** N/A		
7.	**If your answer to the question in item 3 is "yes," do any of the entities disclosed in item 4 have parent organizations, subsidiaries, or partnerships that you are not representing in your testimony?**	**Yes**	**No** X
8.	**If the answer to the question in item 3 is "yes," please list any Federal grants or contracts (including subgrants or subcontracts) that were received by the entities listed under the question in item 4 on or after October 1, 2011, that exceed 10 percent of the revenue of the entities in the year received, including the source and amount of each grant or contract to be listed:** N/A		
9.	**Please attach your curriculum vitae to your completed disclosure form.** SEE ATTACHED		

Signature: [redacted] **Date:** May 16, 2014